Long Acting Injections and Implants
Long acting injections and implants improve therapy, enhance patient compliance, improve dosing convenience, and are the most appropriate formulation choice for drugs that undergo extensive first pass metabolism or that exhibit poor oral bioavailability. An intriguing variety of technologies have b...
| Other Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
New York, NY
Springer New York
2012, 2012
|
| Edition: | 1st ed. 2012 |
| Series: | Advances in Delivery Science and Technology
|
| Subjects: | |
| Online Access: | |
| Collection: | Springer eBooks 2005- - Collection details see MPG.ReNa |
Table of Contents:
- An Introduction to Long Acting Injections and Implants
- Historical Overview of Long Acting Injections and Implants
- Host Response to Long Acting Injections and Implants
- Anatomy and Physiology of the Injection Site – Implications for Extended Release Parenteral Systems
- Drugs for Long Acting Injections and Implants
- Diseases and Clinical Applications that Can Benefit from Long Lasting Implants and Injections
- Oily (lipophilic) Solutions and Suspensions
- Aqueous Suspensions
- In Situ Forming Systems (Depots)
- Microsphere Technologies
- Liposomes as Carriers for Controlled Drug Delivery
- Micro- and Nanoemulsions (Controlled Release Parenteral Drug Delivery Systems)
- Nanosuspensions
- PEGylated Pharmaceutical Nanocarriers
- Protein PEGylation
- Self-Assembling Lipid Formulations
- Implantable Drug Delivery Systems Based on the Principles of Osmosis
- Microtechnologies for Drug Delivery
- Drug Eluting Stents
- Delivery of Peptides and Proteins via Long Acting Injections and Implants
- Injectable PLGA Systems for Delivery of Vaccine Antigens
- Methods of Sterilization for Controlled Release Injectable and Implantable Preparations
- In Vitro Drug Release Testing and In Vivo/In Vitro Correlation for Long Acting Implants and Injections
- Regulatory Issues and Challenges Associated with the Development of Performance Specifications for Modified Release Parenteral Products